exidavnemab - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Why support-platform strategy may become a differentiator in schizophrenia treatment markets

Representative image of gold bars and tanker traffic in the Strait of Hormuz, illustrating why gold prices climbed to a one-month high even as the waterway was declared completely open.

What gold’s latest rally says about geopolitical hedging after the Strait of Hormuz reopening

Representative image of U.S. Air Force defense data infrastructure and enterprise IT systems, illustrating how Dell Technologies’ EMC contract win could support military test data modernization.

Dell Technologies Inc. (NYSE: DELL): What EMC’s $984.3 m Air Force award means for defense IT strategy

Samsung Galaxy M17 5G review: Is this budget Samsung phone worth buying at ₹15,498?

Samsung Galaxy M17 5G at ₹15,498: Hidden budget beast or just another overhyped Samsung phone?

Read More

Pharma Industry News

BioArctic advances exidavnemab phase 2a cohorts after safety review

BioArctic expands its Phase 2a trial for exidavnemab after a successful safety review. Read how this impacts Parkinson’s and MSA drug development today.

byPallavi Madhiraju

June 13, 2025

web analytics